FDA Publishes Rejection Letters to Increase Transparency in Drug Approval Process

TL;DR Summary
The FDA released over 200 letters sent to drug companies regarding rejected medicines, focusing on transparency by compiling these communications, including 14 published for the first time, covering decisions from 2020 to 2024, with some redactions for privacy.
Topics:business#drug-approval-process#drug-rejection-letters#fda#health#pharmaceutical-industry#transparency
- FDA publishes rejection letters sent to drugmakers, with a big caveat STAT
- F.D.A. Posts Collection of Letters Outlining Concerns About New Drugs The New York Times
- Makary targets pharma industry 'spin' as FDA opens rejection letter vault FirstWord Pharma
- FDA, in policy shift, publishes some drug rejection letters BioPharma Dive
- FDA releases ‘initial batch’ of more than 200 drug rejection letters Fierce Biotech
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
87%
283 → 38 words
Want the full story? Read the original article
Read on STAT